REG - Tristel PLC - Trading update

TristelAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250729:nRSc8603Sa&default-theme=true

RNS Number : 8603S  Tristel PLC  29 July 2025

TRISTEL plc

("Tristel" or the "Company")

 

Trading Update

Results in line with market expectations

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces a trading update for the year ended 30 June 2025. The Company
confirms another year of significant growth with results expected to be in
line with market expectations and the Company's own performance targets.

 

The Company continues to see strong demand for its infection prevention
products, with second half revenues increasing by 15% on a constant currency
basis. Consequently:

 

·      Revenues for the year were up 11% to £46.5m (FY 2024: £41.9m),
in line with the Company's performance target for revenue growth (an annual
average of 10-15% over three years).

·      Strong growth (23%) in adjusted profit before tax* which is
expected to be no less than £10.1m, in line with expectations (FY 2024:
£8.2m).

·     Tristel continues to be debt free and cash generative. Cash
balances on 30 June 2025 were £12.8m (30 June 2024: £11.8m).

 

Matt Sassone, Chief Executive Officer of Tristel, commented: "As I approach
the one year mark as CEO, we are pleased to have delivered another year of
strong growth, fully aligned with our strategic targets. Demand for our
infection prevention technologies remains robust across all regions, including
our newly established North American markets.

 

"Achieving 11% revenue growth and a 23% uplift in adjusted profit before tax
reflects both the resilience of our business model and the commitment of our
global team. We have further strengthened our Board with the addition of our
new CFO, Anna Wasyl, who will join us in September, and we look forward to
capitalising on her expertise as we enter the next phase of growth. We remain
debt-free, cash-generative, and confident in our ability to sustain this
momentum as we look to the year ahead."

 

*adjusted for share based payments and exceptional items

 

For further information please contact:

 

 Tristel plc                                                                   Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                         www.investors.tristel.com (https://investors.tristel.com/)

 Walbrook PR Ltd                                                               Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Alice Woodings    Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

 Cavendish Capital Markets Ltd                                                 Tel: 020 7220 0500
 Geoff Nash / Callum Davidson/Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25% and the
business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBUGDRUDDDGUI